Campus News
Home > Campus News > Content

Elsevier publishes a volume of a book co-edited by CQU’s Prof. Li Yongsheng

Recently, Volume 1 Cancer Immunology and Immunotherapy of Delivery Strategies and Engineering Technologies in Cancer Immunotherapy, written under the general editorship of Professor Mansoor M. Amiji and Professor Lara Scheherazade Milane from Northeastern University of the USA, was published globally (SBN 978-0-12-823397-9) by Elsevier. Other co-editors include well-known experts in cancer immunology from 14 countries, such as China, the USA, the UK, Germany and Japan. The monograph is a cutting-edge and authoritative one in the field of cancer immunology and immunotherapy. It provides new theoretical reference for researchers and scholars engaged in research of related areas, and is of extreme significance for promotion of international cooperation and exchange and research of cancer immunology across the world.

This monograph consists of three volumes, titled respectively Cancer Immunology and Immunotherapy, Local Immunotherapy of Cancer and stasis, and Engineering Technologies and Clinical Translation. Specifically, Volume 1 is divided into 15 chapters on the following topics: Characteristics of cancer and immunity, natural and acquired immunity of cancer, inflammation and cancer, new methods of cancer immunotherapy, immune editing and carcinogenesis, cancer metabolic reprogramming and immunity, epigenetic programming of tumor immune response, cell therapy of tumor immunity, bispecific antibody therapy involving T cells, the role of microbiome in tumor immunotherapy Sting pathway and tumor immunotherapy regulation, oncolytic virus in immunotherapy, comparison of tumor immunotherapy strategies, intrinsic and acquired cancer immunotherapy resistance, pre-clinical and clinical toxicity and mitigation strategies of tumor immunotherapy.

Due to his academic influence in the area of cancer immune metabolism, Professor Li Yongsheng, director of the Department of Medical Oncology of Chongqing University Cancer Hospital, became the only expert from China who is responsible for compilation of Chapter VI, bolic reprogramming and immunity in cancer, of Volume 1 of the monograph. Chen Yu, a full-time researcher of the Department of Medical Oncology is the first author of this chapter. Li Yongsheng is the corresponding author. This chapter briefly describes the progress of cancer immunotherapy, the metabolic reprogramming of tumor cells and immune cells, the regulatory role of glucose, lipid, amino acid and mitochondrial metabolism in tumor immunotherapy, as well as the impact of symbiotic microorganisms on the host immune system and the occurrence and development of cancer, and puts forward potential metabolic targets in cancer immunotherapy.

Cancer immunotherapy is at present the most promising anti-cancer therapy that treats cancer by activating the immune system. The related research has resulted in encouraging results. However, due to the diversity of cancer cell immune escape mechanism, its therapeutic response still needs to be improved. A large number of studies have shown that the metabolic reprogramming of cancer cells and immune cells and the metabolism of symbiotic microorganisms play an important regulatory role in anti-tumor immunity and tumor immune escape, and play a common role in the occurrence and development of tumors. In addition, the metabolism of three nutrients (glucose, lipid and amino acids) and mitochondrial metabolism not only provide necessary materials and energy for cells, but also participate in the regulation of a variety of cell activities and signal transduction. This Chapter summarizes the metabolic reprogramming and cancer immune regulation of cancer progression in a comprehensive manner, and is expected to provide a new and effective strategy for cancer immunotherapy.